1. Korean Helicobacter pylori Study Group. Diagnosis and treatment for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 1998; 32:275–289.
2. Lee YC, Lee SY, Pyo JH, Kwon DH, Rhee JC, Kim JJ. Isogenic variation of Helicobacter pylori strain resulting in heteroresistant an-tibacterial phenotypes in a single host in vivo. Helicobacter. 2005; 10:240–248.
3. National Committee for Clinical Laboratory Standards. Acceptable limits for quality control strains used to monitor accuracy of minimal inhibitory concentrations of fastidious organisms. Performance standards for antimicrobial susceptibility testing, 12th informational supplement M100-S12. 22:no. 1.Wayne (PA): NCCLS;2002. p. 117–121.
4. Kim JG. Treatment of Helicobacter pylori infection. Korean J Gastroenterol. 2005; 46:172–180.
5. Gisbert JP, Marcos S, Gisbert JL, Pajares JM. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol. 2001; 13:1303–1307.
6. Chung SJ, Lee DH, Kim N, et al. Eradication rates of Helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease. Hepatogastroenterology. 2007; 54:1293–1296.
7. Kim JY, Kim N, Kim JM, et al. Primary antibiotic resistance of Helicobacter pylori strains and eradication rate depending on gastroduodenal disease. Korean J Gastroenterol. 2011; 58:74–81.
8. Kim JM. Antibiotic resistance of Helicobacter pylori isolated from Korean patients. Korean J Gastroenterol. 2006; 47:337–349.